Protagonist Therapeutics, Inc (PTGX) is a publicly traded Healthcare sector company. As of August 19, 2026, PTGX trades at $157.51 with a market cap of $10.26B and a P/E ratio of -77.14. PTGX moved -0.74% today. Year to date, PTGX is +80.15%; over the trailing twelve months it is +179.91%. Its 52-week range spans $33.70 to $160.00. Analyst consensus is strong buy with an average price target of $162.45. Rallies surfaces PTGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
11 analysts cover PTGX: 0 strong buy, 11 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $162.45.
| Metric | Value |
|---|---|
| Price | $157.51 |
| Market Cap | $10.26B |
| P/E Ratio | -77.14 |
| EPS | $-2.05 |
| Dividend Yield | 0.00% |
| 52-Week High | $160.00 |
| 52-Week Low | $33.70 |
| Volume | 325.45K |
| Avg Volume | 0 |
| Revenue (TTM) | $46.02M |
| Net Income | $-130.15M |
| Gross Margin | 0.00% |
11 analysts cover PTGX: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $162.45.